Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2024 Filed Jun 12, 2024 21:19 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 5,000 | $45.28 | $226,383.50 |
DisclosureSEC source: 0001225208-24-006780 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,935.7184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| May 30, 2024 Filed May 30, 2024 21:10 UTC |
Zovighian Bernard JDirector · CEO
|
SaleCommon Stock | 8,617 | $87.68 | $755,538.56 |
DisclosureSEC source: 0001225208-24-006448 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,217.9005 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024. Read SEC document |
| May 21, 2024 Filed May 21, 2024 21:09 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,625 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-006287 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,875 Underlying: Common Stock · 5,625 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 21, 2024 21:09 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 5,625 | $90.45 | $508,803.19 |
DisclosureSEC source: 0001225208-24-006287 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.225 to $90.720. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2024 Filed May 21, 2024 21:09 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 5,625 | $45.28 | $254,681.44 |
DisclosureSEC source: 0001225208-24-006287 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:47 UTC |
SELLERS ROBERT W.A.SVP, Corporate Controller
|
Tax withholdingCommon Stock | 229 | $86.72 | $19,858.88 |
DisclosureSEC source: 0001225208-24-005986 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,081.198 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:47 UTC |
Szyman Catherine M.CVP, Critical Care
|
Tax withholdingCommon Stock | 827 | $86.72 | $71,717.44 |
DisclosureSEC source: 0001225208-24-005985 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,165.4373 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:47 UTC |
Wood Larry LGlobal President TAVR & Surg
|
Tax withholdingCommon Stock | 985 | $86.72 | $85,419.20 |
DisclosureSEC source: 0001225208-24-005984 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,525.739 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:46 UTC |
Lippis Daniel J.CVP, JAPAC
|
Tax withholdingCommon Stock | 377 | $86.72 | $32,693.44 |
DisclosureSEC source: 0001225208-24-005983 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,512.7443 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:46 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
Tax withholdingCommon Stock | 21 | $86.72 | $1,821.12 |
DisclosureSEC source: 0001225208-24-005982 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,767.8055 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:45 UTC |
Chopra DaveenCVP, TMTT
|
Tax withholdingCommon Stock | 821 | $86.72 | $71,197.12 |
DisclosureSEC source: 0001225208-24-005981 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,583 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:45 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 814 | $86.72 | $70,590.08 |
DisclosureSEC source: 0001225208-24-005980 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,935.7184 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:45 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 2,854 | $86.72 | $247,498.88 |
DisclosureSEC source: 0001225208-24-005979 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,834.9005 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:45 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,198 | $86.72 | $103,890.56 |
DisclosureSEC source: 0001225208-24-005978 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,561 Read SEC document |
| May 10, 2024 Filed May 13, 2024 21:45 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-005980 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,500 Underlying: Common Stock · 5,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2024 Filed May 13, 2024 21:45 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
SaleCommon Stock | 5,000 | $87.81 | $439,038.00 |
DisclosureSEC source: 0001225208-24-005980 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,749.7184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $87.415 to $88.050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2024 Filed May 13, 2024 21:45 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 5,000 | $45.28 | $226,383.50 |
DisclosureSEC source: 0001225208-24-005980 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,749.7184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:43 UTC |
LORANGER STEVEN RDirector
|
GrantCommon Stock | 999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005898 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,372 F2 · shares: This restricted stock award was granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:43 UTC |
LORANGER STEVEN RDirector
|
GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005898 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,373 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:42 UTC |
VALERIANI NICHOLAS JDirector
|
GrantCommon Stock | 4,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005897 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,732 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:42 UTC |
Sequeira RamonaDirector
|
GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005896 · doc4.xml · nonDerivative · entry 1 Sequeira Ramona · CIK 0001811081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,158 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:42 UTC |
LAVIOLETTE PAUL ADirector
|
GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005895 · doc4.xml · nonDerivative · entry 1 LAVIOLETTE PAUL A · CIK 0001191249 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,773 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:41 UTC |
STONE HEISZ LESLIEDirector
|
GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005894 · doc4.xml · nonDerivative · entry 1 STONE HEISZ LESLIE · CIK 0001235408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,035 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:41 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005893 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,054 F2 · shares: This restricted stock award was granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:41 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005893 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,055 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:41 UTC |
Davis Leslie C.Director
|
GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005892 · doc4.xml · nonDerivative · entry 1 Davis Leslie C. · CIK 0002021765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,055 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:41 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantPerformance Rights · Derivative | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005891 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:41 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 39,600 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005891 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,600 Underlying: Common Stock · 39,600 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:41 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 619 | $85.09 | $52,670.71 |
DisclosureSEC source: 0001225208-24-005891 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,749.7184 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:41 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005891 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,368.7184 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
GrantPerformance Rights · Derivative | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · derivative · entry 8 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,900 Underlying: Common Stock · 2,900 shares Expires not disclosed F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 857 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · derivative · entry 7 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 857 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 15,500 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · derivative · entry 6 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-05-06 F3 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
SaleCommon Stock | 857 | $85.60 | $73,359.20 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,889.7443 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
Tax withholdingCommon Stock | 586 | $85.09 | $49,862.74 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,746.7443 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
Exercise / conversionCommon Stock | 857 | $36.75 | $31,494.75 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,332.7443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,475.7443 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Lippis Daniel J.CVP, JAPAC
|
GrantCommon Stock | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,575.7443 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Chopra DaveenCVP, TMTT
|
GrantPerformance Rights · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Chopra DaveenCVP, TMTT
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 37,200 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Chopra DaveenCVP, TMTT
|
Tax withholdingCommon Stock | 447 | $85.09 | $38,035.23 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,404 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC |
Chopra DaveenCVP, TMTT
|
GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,851 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
GrantPerformance Rights · Derivative | 7,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005888 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 7,125 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 42,200 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005888 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,200 Underlying: Common Stock · 42,200 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
Tax withholdingCommon Stock | 46 | $85.09 | $3,914.14 |
DisclosureSEC source: 0001225208-24-005888 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,788.8055 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
GrantCommon Stock | 7,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005888 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,834.8055 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Wood Larry LGlobal President TAVR & Surg
|
GrantPerformance Rights · Derivative | 8,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005887 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,725 Underlying: Common Stock · 8,725 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Wood Larry LGlobal President TAVR & Surg
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 51,700 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005887 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Wood Larry LGlobal President TAVR & Surg
|
Tax withholdingCommon Stock | 695 | $85.09 | $59,137.55 |
DisclosureSEC source: 0001225208-24-005887 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,510.739 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:39 UTC |
Wood Larry LGlobal President TAVR & Surg
|
GrantCommon Stock | 8,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005887 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,205.739 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.